Infliximab for the treatment of ulcerative colitis

References

• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet369, 1641–1657 (2007).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology126, 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol.99, 1371–1385 (2004).
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lémann M et al. European evidence-based consensus on the management of ulcerative colitis: current management. Gut (55 Suppl.1), I16–I35 (2006).
   Google Scholar
• Reinisch W, Sandborn WJ, Bala M et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm. Bowel Dis.13, 1135–1140 (2007).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment. Pharmacol. Ther.27(Suppl. 1), 15–21 (2008).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment. Pharmacol. Ther.11, 1053–1057 (1997).
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur. J. Gastroenterol. Hepatol.8, 549–553 (1996).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm. Bowel Dis.12, 979–994 (2006).
   PubMed Web of Science ®Google Scholar
• Campieri M, Adamo S, Valpiani D et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther.17, 1471–1480 (2003).
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet1, 1067–1070 (1974).
   PubMed Web of Science ®Google Scholar
• Van Assche G, D’Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology125, 1025–1031 (2003).
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst. Rev.3, CD007216 (2008).
   Google Scholar
• Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med.330, 1841–1845 (1994).
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology107, 3–11 (1994).
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm. Bowel Dis.12, 543–550 (2006).
   PubMed Web of Science ®Google Scholar
• Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig. Surg.22, 69–79 (2005).
   PubMed Web of Science ®Google Scholar
• Remicade® (infliximab), summary of product characteristics. Centocor Inc., PA, USA (2008).
   Google Scholar
• Remicade® (infliximab), prescribing information. Centocor Inc., PA, USA (2008).
   Google Scholar
• Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther.28, 674–688 (2008).
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA72, 3666–3670 (1975).
   PubMed Web of Science ®Google Scholar
• Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit. Care Med.17, 489–494 (1989).
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor a in stool as a marker of intestinal inflammation. Lancet339, 89–91 (1992).
   PubMed Web of Science ®Google Scholar
• Brennan FM, Maini RN, Feldmann M. TNF α – a pivotal role in rheumatoid arthritis? Br. J. Rheumatol.31, 293–298 (1992).
   PubMedGoogle Scholar
• Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol. Immunol.30, 1443–1453 (1993).
   PubMed Web of Science ®Google Scholar
• Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol.2, 364–371 (2002).
   PubMed Web of Science ®Google Scholar
• Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv. Immunol.64, 283–350 (1997).
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology109, 129–135 (1995).
   PubMed Web of Science ®Google Scholar
• Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn’s disease: one-year experience in a Dutch academic hospital. Inflamm. Bowel Dis.8, 81–86 (2002).
   PubMed Web of Science ®Google Scholar
• Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor-α blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev.3, CD005112 (2006).
   Google Scholar
• Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology125, 145–153 (2008).
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet.46, 645–660 (2007).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117, 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. Drugs65, 2179–2208 (2005).
   PubMed Web of Science ®Google Scholar
• Boyle A, Tawadros R, Zhu Y. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn’s disease patients. Gastroenterology122, A614–A615 (2002).
   PubMed Web of Science ®Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology128, 1805–1811 (2005).
   PubMed Web of Science ®Google Scholar
• Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut52, 998–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353, 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis.7, 83–88 (2001).
   PubMed Web of Science ®Google Scholar
• Armuzzi A, De PB, Lupascu A et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci.8, 231–233 (2004).
   PubMedGoogle Scholar
• Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur. J. Gastroenterol. Hepatol.16, 1167–1171 (2004).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther.25, 19–37 (2007).
   PubMed Web of Science ®Google Scholar
• Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am. J. Gastroenterol.87, 971–976 (1992).
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med.317, 1625–1629 (1987).
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J.1, 89–92 (1964).
   PubMed Web of Science ®Google Scholar
• Nordin K, Pahlman L, Larsson K, Sundberg-Hjelm M, Loof L. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand. J. Gastroenterol.37, 450–457 (2002).
   PubMed Web of Science ®Google Scholar
• Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm. Bowel Dis.14, 554–565 (2008).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Reinisch W, Rutgeerts P et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am. J. Gastroenterol.102, 794–802 (2007).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology129, 1358–1359 (2005).
   PubMedGoogle Scholar
• Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol.6, 1112–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Periodical Safety Update Report (PSUR) 2008. Centocor Inc., PA, USA (2008).
   Google Scholar
• Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf.7, 617–632 (2008).
   PubMed Web of Science ®Google Scholar
• Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am. J. Gastroenterol.99, 2385–2392 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol.4, 621–630 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Prantera C, Rutgeerts P et al. No new safety signals identified in Crohn’s disease patients treated with infliximab in an interim review of the ENCORE registry. Gastroenterology,134, A472 (2008).
   Google Scholar
• Ulcerative Colitis European Registry. A Prospective, Observational, Non-interventional, Post-marketing Safety Surveillance Program. Schering-Plough Research Institute, NJ, USA (2008).
   Google Scholar
• Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut57, 1639–1641 (2008).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut56, 1226–1231 (2007).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology126, 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Deshpande AR, Abreu MT. Combination therapy with infliximab and immunomodulators: is the glass half empty? Gastroenterology134, 2161–2163 (2008).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology134, 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut56, 1181–1183 (2007).
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology134, 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther.26, 747–756 (2007).
   PubMed Web of Science ®Google Scholar
• Lees CW, Heys D, Ho GT et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharmacol. Ther.26, 411–419 (2007).
   PubMed Web of Science ®Google Scholar
• Mor IJ, Vogel JD, da Luz MA, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis. Colon Rectum51, 1202–1207 (2008).
   PubMed Web of Science ®Google Scholar
• Selvasekar CR, Cima RR, Larson DW et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J. Am. Coll. Surg.204, 956–962 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrante M, D’Hoore A, Vermeire S et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm. Bowel Dis. DOI:10.1002/ibd.20863 (2009) (Epub ahead of print).
   Google Scholar
• O’Donnell S, O’Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment. Pharmacol. Ther.27, 885–894 (2008).
   PubMed Web of Science ®Google Scholar
• Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J. Gastroenterol.14, 3085–3087 (2008).
   PubMed Web of Science ®Google Scholar
• Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis.11, 213–218 (2005).
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr.38, 298–301 (2004).
   PubMed Web of Science ®Google Scholar
• Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J. Pediatr. Gastroenterol. Nutr.39, 166–170 (2004).
   PubMed Web of Science ®Google Scholar
• McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J. Clin. Gastroenterol.42, 875–879 (2008).
   PubMed Web of Science ®Google Scholar
• Franke A, Balschun T, Karlsen TH et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet.40, 1319–1323 (2008).
   PubMed Web of Science ®Google Scholar